Bellevue Life Sciences Acquisition closed the full over-allotment option for 900,000 units to the underwriters of its IPO, with total gross proceeds of $69 million from the offering.
Units list on the Nasdaq under the ticker symbol BLACU. Each consists of one share, a warrant and one right good for one-tenth of a share once the SPAXC completes a merger.
The biotech-focused SPAC was formed by Bellevue Capital Management.
After the securities begin separate trading, shares, warrants and rights are expected to list under the symbols BLAC, BLACW and BLACR, respectively.
Chardan was sole book-running manager of the offering. Read more.
